Icosagen In The News

A UNITED STATES PATENT HAS BEEN GRANTED TO THE QMCF TECHNOLOGY

The United States Patent and Trademark Office granted on 07 September 2010 a Patent No US 7790446 B2 with the title “Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products” to Icosagen Cell Factory that is related to the QMCF Technology.

QMCF Technology has been established for the efficient production of biologically active substances, such as proteins, antibodies and virus-like particles for research purposes and development of biological therapeutics. The QMCF Technology is a stable, multicopy episomal expression system that provides high expression levels and significantly reduces the timeline for protein and antibody production. In addition, it is applicable in constructing test-systems (cell-based assays) for drug target screening, large scale protein and antibody production, etc.

About Icosagen Cell Factory

Icosagen Cell Factory OÜ was established in 2005. The company is dedicated to the development of the portfolio of QMCF technology-based applications. 

About Icosagen Group

The Icosagen Group’s activity began in 1999, with the founding of molecular diagnostic company Quattromed AS. In 2001, the development of technologies and products based on molecular and cellular biology began. Today, the Icosagen Group comprises of Icosagen AS and Icosagen Cell Factory OÜ. The activities of the company include the development, production and sale of biochemical, immunoassay, molecular and cellular biology products and services.